Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

Study Results Demonstrated Significant Weight Loss in Obese Patients Treated with Qnexa

MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the previously reported 28-week phase 3 EQUATE trial of Qnexa(TM) in obese patients are being presented today at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. The results, titled "Weight Loss at 6 Months with VI-0521 Treatment," will be presented at the Hot Topic poster session by Donna H. Ryan, M.D., Associate Executive Director for Clinical Research, Pennington Biomedical Research Center in Baton Rouge, LA. The presentation marks the first time these results have been shared with the medical community at a major medical meeting.

The phase 3 EQUATE trial evaluated weight loss achieved with two doses of Qnexa versus that achieved with placebo among 756 patients over 28 weeks. Patients taking full-dose and mid-dose Qnexa achieved an average weight loss of 9.2 percent and 8.5 percent, respectively, as compared to 1.7 percent reported for the placebo group. All results were evaluated using ITT-LOCF, the method of analysis required by the U.S. Food and Drug Administration.

"Obesity has reached epidemic proportions, affecting more than 300 million people worldwide and contributing to increased prevalence of life-threatening illnesses such as hypertension, diabetes, cardiovascular disease and stroke. Patients are in urgent need of new, safe and effective tools to help them achieve the weight loss critical to their health and wellbeing," said Dr. Ryan. "The weight loss seen in patients taking Qnexa, over just 28 weeks, is encouraging for those of us in the medical community treat
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Isis Pharmaceuticals, ... data from three drugs in its lipid franchise were ... of Cardiology (ESC) Congress in Barcelona Spain ... antisense drugs designed to provide effective and safe therapeutic ... is composed of one commercialized drug and several other ...
(Date:9/2/2014)... , Switzerland , September ... receiving ISO 13485 accreditation, Sophia Genetics has become the ... clinical use of a Next Generation Sequencing (NGS) ... certification represents an important step in raising the ... and brings Sophia Genetics, world-leading Data Driven Medicine ...
(Date:9/2/2014)... Sept. 2, 2014  Sinovac Biotech Ltd. (NASDAQ: ... China , today announced that the Company,s management ... , Morgan Stanley Global Healthcare Conference, to be held ... 10, 2014. , Morgan Stanley Asia Pacific Healthcare Day, ... 11, 2014. , Aegis Healthcare & Technology Conference, to ...
Breaking Medicine Technology:Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2Sinovac to Participate in Upcoming Investor Conferences 2
... (Nasdaq: ANTH ), a biopharmaceutical company developing ... autoimmune disorders, will release its first quarter 2012 financial ... Anthera will host a conference call at 8:30 am ... Conference Call Access: Date: Friday, May 4, 2012 Time: 8:30 ...
... for Disease Control reports annual deaths involving opioid pain ... in the United States. In New York and North ... abusing prescription medications continues to rise, sparking attention amongst ... care for those suffering from pain. For these reasons, ...
Cached Medicine Technology:Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 2Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 3Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 4
(Date:9/2/2014)... Growing public support for marijuana legalization in the U.S. ... "safer" than other substances, such as alcohol. In January, ... that marijuana is more dangerous than alcohol. Despite the ... use as compared to alcohol use are not well ... Psychosocial Outcomes Associated with Drug Use among US High ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Smile Squared, ... their product offering to include a US-made toothbrush. For ... child without one. , “Smile Squared was created by ... clinic in Guatemala,” said Eric Cope, President of Smile ... sometimes severe dental problems. But many of the same ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
(Date:9/2/2014)... fact that mechanical heart valves increase risks during and ... ROPAC registry presented for the first time today in ... W. Roos-Hesselink, co-chair with Professor Roger Hall of the ... pregnant women with a mechanical heart valve died and ... Of Pregnancy And Cardiac disease (ROPAC) is an ongoing ...
Breaking Medicine News(10 mins):Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3
... Group of the Bellvitge Biomedical Research Institute (IDIBELL) have ... MDM2 protein, stimulates the signalling pathway of another protein, ... senescence (loss of proliferative capacity) in brain cancer, a ... door for MDM2 agonists as new treatments for glioblastomas. ...
... European Molecular Biology Organization (EMBO) today announced Simon Boulton ... Laboratories as the winner of the 2011 EMBO Gold ... outstanding contributions of young researchers in the molecular life ... his groundbreaking research on DNA repair mechanisms. The election ...
... Neuropsychopharmacology (ECNP) is pleased to announce Bertil Fredholm ... Award in Basic Science Research in recognition of ... The ECNP Neuropsychopharmacology Award is presented annually and ... disciplines. The award is accompanied by a prize ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- The ... Alzheimer,s disease could double the number of Americans defined as ... the Alzheimer,s Association and the U.S. National Institute of Aging, ... have been in use since 1984. First, Alzheimer,s ...
... What race best describes your background? That one question, ... leave entire groups of people underserved and contribute to ... University published in the current issue of the journal ... patients to identify a single race can alter patterns ...
... in patients with high-grade glioma from chemoradiation may result ... oncologists at the Kimmel Cancer Center at Jefferson ... April issue of the British Journal of ... of early side effects, such as fatigue and loss ...
Cached Medicine News:Health News:Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors 2Health News:EMBO Gold Medal 2011 awarded to Simon Boulton 2Health News:EMBO Gold Medal 2011 awarded to Simon Boulton 3Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Limitations of question about race can create inaccurate picture of health-care disparities 2Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: